Literature DB >> 22549057

Why using Avastin for eye disease is so difficult.

Ingrid Torjesen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22549057     DOI： 10.1136/bmj.e3012

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Bevacizumab versus ranibizumab: why are we not playing the joker?

Authors:  Roberto Banfi; Francesco Attanasio; Nadia Palazzi; Silvia Colombini; Tiziana Falai; Michele Cecchi; Gianni Virgili
Journal:  Int J Clin Pharm       Date:  2013-08

Review 2.  Essential medicines for universal health coverage.

Authors:  Veronika J Wirtz; Hans V Hogerzeil; Andrew L Gray; Maryam Bigdeli; Cornelis P de Joncheere; Margaret A Ewen; Martha Gyansa-Lutterodt; Sun Jing; Vera L Luiza; Regina M Mbindyo; Helene Möller; Corrina Moucheraud; Bernard Pécoul; Lembit Rägo; Arash Rashidian; Dennis Ross-Degnan; Peter N Stephens; Yot Teerawattananon; Ellen F M 't Hoen; Anita K Wagner; Prashant Yadav; Michael R Reich
Journal:  Lancet       Date:  2016-11-08       Impact factor: 79.321

3.  The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package.

Authors:  Thunyarat Anothaisintawee; Pattara Leelahavarong; Tanapat Ratanapakorn; Yot Teerawattananon
Journal:  Clinicoecon Outcomes Res       Date:  2012-12-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.